Rexahn Pharmaceuticals regains compliance with NYSE

ROCKVILLE, Md. A leader in innovative therapeutics for life-threatening and life-debilitating diseases announced it has regained compliance with NYSE Amex, formerly known as the American Stock Exchange.

Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain their quality of life.